Former CEO, Beigene
Search every verified John Oyler interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. John Oyler, former CEO of BeiGene and now CEO of BeOneMedicines, has been discussing the state of the biotech industry and his company's strategic focus. In a November 2025 interview, Oyler expressed a positive outlook for biotech, citing significant scientific breakthroughs in modalities such as ADCs, bispecific antibodies, and T-cell engagers. He noted that there remains unmet medical need in oncology, with 10 million cancer deaths annually, and described the progress in science as "crazy" with potential for huge impact. Oyler also discussed the future of antibody therapies, stating that while there is still space for unarmed antibodies, much focus is on more customized approaches, including conjugating antibodies with degraders to target tissues precisely. In earlier interviews from 2024, Oyler detailed BeiGene's strategy of building internal capabilities in manufacturing and clinical development, including a focus on protein degradation and biologics manufacturing. He emphasized the company's approach to board transparency, sharing the "worst things we're worried about" rather than just successes. Oyler also discussed the impact of China's evolving regulatory system and reimbursement of innovative medicines, stating that including China in clinical trials could change fundamental economics and make drugs more affordable globally. He described BeiGene's aspiration to be a "lasting major global player" and a "global leader from China."
“The scientific breakthroughs we're seeing in biotech have the potential to have a huge impact, especially in fighting cancer, where 10 million people die every year. The progress in modalities like ADCs and T-cell engagers is unbelievable.”
“There's still a lot of space in the future for antibodies that aren't armed or directed like the single or kitruder, and we're heavily working on conjugating antibodies with degraders to target tissues more precisely.”
“The biotech industry has improved significantly since January, and I am very bullish on its prospects next year, especially given the unmet medical needs and scientific breakthroughs we are witnessing.”
“The progress we're making with science, especially in targeted therapies like ADCs and T-cell engagers, is crazy and has the potential to revolutionize cancer treatment.”
“The biotech sector's mood has improved a lot, and with the scientific advances, we are optimistic about helping patients and adding value to the world.”
“When you look at the economics associated with our industry there's one striking realization: for most oncology medicines brought to patients over 75% of the cost is driven by clinical trials — today people tell me 250 to 300,000 dollars per patient enrolled — and for a program like brenza that's a program of over 5,00...”
“We thought the reason clinical trial costs were high was threefold: we weren't involving enough centers globally so enrollment times were long, technology still relies on manual double entry prone to errors, and many trials are run by third‑party CROs that have roughly a 30% markup and no incentive to make things more...”
“I'm an American and I'm a capitalist, so I believe in creating an open, fair system that is as competitive as possible — I don't believe government price control is the best way to solve the pricing problem; we should focus on policies that drive transparency and a competitive landscape.”
“When we launched brenza in the United States we actually launched at the lowest price in our class — that's part of who we are as a company, and because of the things we've done to lower cost structure it's possible to price lower and still build a very sustainable, profitable business.”
“We began manufacturing our PD‑1 in Germany with BI and suddenly one day were told you can't manufacture here anymore because a major pharmaceutical company had locked up that site — that setback taught us the importance of owning manufacturing and led us to build our own capabilities, including the roughly $800 million...”
“We committed years ago to move into modalities like protein degraders and EGFR degraders because they fit what we can already do well — we're investing in bispecifics, ADCs and related platforms, but we purposely haven't jumped into radiopharmaceuticals or become a major mRNA player; instead we're trying to solve the f...”
“When capital flows you can invest in capabilities, but when markets turn you have to be really careful with your pennies; you need clarity on whether you want to build a long‑term sustainable company and be realistic about what capabilities you must own to have an advantage.”
“We've tried to have very big transparency with our board — we share the worst things we're worried about, not just brag about successes — because people who truly help you won't always agree with you and that makes the company stronger.”
“When you look at that there's one striking realization for most oncology medicines brought to patients over 75% of the cost is driven by clinical trials and that's a cost that has dramatically increased over time. Today when I talk to my peers they say 250 to 300,000 per patient enrolled on a clinical trial.”
“Part of our view was the reason clinical trial costs were high was threefold: the first was we just weren't involving enough centers here in the United States and across the globe in clinical trials... second perspective... technology needs to improve... and thirdly a lot of the clinical trials the vast majority are ru...”
Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap ...
Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap ...
John Oyler, CEO and Co-Founder of BeiGene, talks about BeiGene's long-term partnership with Hillhouse Investment and how ...
John Oyler is the CEO and cofounder of global biotech outfit BeiGene. He owns about 5% of the publicly traded company.
John V. Oyler co-founded BeiGene in 2010. He has served as CEO and a member of the Board of Directors from the company's ...
Keynote: "How China is Transforming the Clinical Development Landscape & the Biopharma Industry" by John Oyler, Co-Founder ...
The GapSummit 2020 Day 2 opening session was a panel discussion on Collaboration Across Global Bioeconomies. Chaired by ...
GapSummit 2020 Fireside Chat with John Oyler, Founder & CEO, BeiGene. Hosted by Dr Brindan Suresh, Partner, McKinsey ...
GapSummit 2020 Fireside Chat: John Oyler (Founder & CEO, BeiGene), hosted by Dr Brindan Suresh (Partner, McKinsey ...
Sign in to search the full transcript archive, filter by topic, and access every quote from John Oyler.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →